Wells Fargo & Company Eledon Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ELDN
# of Institutions
34Shares Held
18.4MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA6.29MShares$25.2 Million0.5% of portfolio
-
Armistice Capital, LLC New York, NY2.36MShares$9.46 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$6.26 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY1.5MShares$6 Million0.03% of portfolio
-
Zimmer Partners, LP New York, NY1.43MShares$5.74 Million0.07% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $55M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...